GELESIS HOLDINGS, INC.

Gelesis Holdings, Inc. was formed through the de-SPAC merger of Capstar Special Purpose Acquisition Corp. (Nasdaq: CPSR), a blank-check company that completed its IPO in 2020 and was sponsored by Capstar Acquisition Sponsor LLC. The company operates in the healthcare and biotechnology sector, focused on the development and commercialization of superabsorbent hydrogel-based therapeutics for chronic diseases linked to the gastrointestinal pathway, including its FDA-cleared weight management treatment, Plenity. The February 2022 S-1 registration statement was filed shortly after the business combination closed, transitioning the combined entity to trade on the New York Stock Exchange under the ticker GLS. Visit SpacDesk and sign up for full data, filings, and deal analytics on this and hundreds of other SPAC transactions.